News
Lenalidomide plus dexamethasone in multiple myeloma

https://doi.org/10.1016/S1470-2045(17)30894-XGet rights and content

References (0)

Cited by (5)

  • Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma

    2022, Biomaterials
    Citation Excerpt :

    Lenalidomide is a prime candidate for the treatment of DLBCL due to its immunomodulatory properties [15,16], especially in patients with an inflammatory microenvironment, but lenalidomide has non-negligible side effects [17,18]. Lenalidomide combination with dexamethasone (Dex) was widely accepted for the treatment of MM and showed significant improvement in efficacy [19–21], which also provided a new strategy for DLBCL therapy. However, the simultaneous delivery of lenalidomide and dexamethasone can alleviate the toxic and side effects of lenalidomide on liver and kidney tissues in-clinic therapy [22].

  • Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma

    2019, Journal of Controlled Release
    Citation Excerpt :

    In regimens used to treat patients suffering from MM, dexamethasone is typically combined with other chemotherapeutic agents such as proteasome inhibitors (bortezomib and carfilzomib), immune modulators (thalidomide and lenalidomide), and cyclophosphamide or melphalan [9]. Dexamethasone has shown to improve clinical outcomes in MM patients when part of the treatment regimens [10–13]. However, GCs have off-target adverse effects like strong systemic immunosuppression, which can lead to opportunistic infections which, when not treated successfully, can result in death [2].

View full text